Rani Therapeutics Soars 250% on $1.08B Pharma Deal and $60M Funding
Rani Therapeutics Holdings (RANI), a penny biotech stock, surged nearly 250% following a landmark $1.08 billion licensing agreement with Chugai Pharmaceutical, a Roche subsidiary. The deal focuses on developing an oral version of a rare disease therapy using Rani's proprietary RaniPill capsule technology combined with Chugai's antibody drug. Potential payouts include upfront payments, development milestones, and royalties, signaling strong validation from a major pharmaceutical player.
Concurrently, Rani secured $60.3 million in an oversubscribed private placement, extending its operational runway into 2028. Investors are now monitoring progress on the Chugai collaboration and Rani's internal drug pipeline, which could redefine oral biologic treatments.
